• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Leadership Update

    5/22/26 5:00:14 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $COEP alert in real time by email
    COEPTIS THERAPEUTICS HOLDINGS, INC. 8-K
    false 0001759186 0001759186 2026-05-22 2026-05-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _____________________

    FORM 8-K

    _____________________

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of Earliest Event Reported): May 22, 2026

    _____________________

     

    Z Squared Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 001-39669 98-1465952

    (State or other jurisdiction of incorporation)

    (Commission File Number)

    (I.R.S. Employer Identification No.)

         

    550 South Andrews Ave., Suite #700

    Fort Lauderdale, Florida

      33301
    (Address of principal executive offices)   (Zip Code)

     

    954-400-9994

    (Registrant’s telephone number, including area code)

     

    ________________________________________

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    ZSQR

     

    Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

    Emerging growth company     ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

     

     

     

       
     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Resignation of Co-Chief Executive Officer and Director.

     

    On May 22, 2026, Michelle Burke notified the Board of Directors (the “Board”) of Z Squared Inc. (the “Company”) of her resignation as Co-Chief Executive Officer and director of the Company, effective May 22, 2026. The Board accepted Ms. Burke’s resignation on the same date.

     

    Ms. Burke’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. As of the date of this Current Report on Form 8-K, the Board has not appointed a successor to fill the vacancy on the Board created by Ms. Burke's resignation.

     

    Ms. Burke will be returning to Minting Dome, Inc. (“Minting Dome”). The Company’s existing Master Services Agreement with Minting Dome remains in effect in accordance with its terms.

     

    Continuation of David Halabu as Chief Executive Officer.

     

    Following Ms. Burke’s resignation described in Item 5.02(b) above, David Halabu, who had served as a Co-Chief Executive Officer of the Company alongside Ms. Burke since April 24, 2026, will continue to serve as the sole Chief Executive Officer of the Company, effective May 22, 2026.

     

    David Halabu, age 50, has served as a Co-Chief Executive Officer of the Company since the closing of the Company's business combination on April 24, 2026, and effective May 22, 2026, serves as the sole Chief Executive Officer of the Company. Mr. Halabu has also served as Chief Executive Officer of Z Squared OpCo Inc., the Company's wholly-owned operating subsidiary (formerly known as Z Squared, Inc., a Wyoming corporation), since June 2024. Mr. Halabu started his career as a trader at Broadway Training in New York City then moved on to head the trading desk for Assent LLC in South Florida from 2001 to 2011. In 2013, he co-founded Group 10 Capital Management LLC to invest in non-performing real estate debt, and it has since evolved to have separate divisions for private lending, commercial value-add and residential rentals. He has been an avid real estate entrepreneur as well as an investor in many alternatives such as real estate, distressed debt and operating businesses. In the last five years, Mr. Halabu has owned and operated a Remediation and Construction company in South Florida, as well as been an active investor in a number residential and commercial real estate projects in Florida, Michigan, and the Carolinas. He began working with Broadstreet Inc., in late 2021 and had an active role on both capital markets and business strategy. Additionally, he is a member of Entrepreneurs Organization and Chartered Alternative Investment Analysts (CAIA). Mr. Halabu graduated as a Deans Honors Scholar from Tulane University (La.) with a BS in Economics and minor in Mathematics.

     

    There are no family relationships between Mr. Halabu and any director or executive officer of the Company, and there are no arrangements or understandings between Mr. Halabu and any other person pursuant to which he was selected as Chief Executive Officer.

     

    There were no changes to Mr. Halabu’s compensation arrangements with the Company in connection with the foregoing.

     

     

     

     

     2 

     

     

    SIGNATURES

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

     

      Z SQUARED INC.
       
       
    Date: May 22, 2026 By: /s/ Brian Cogley                      
     

          Name: Brian Cogley

          Title:   Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     3 

     

    Get the next $COEP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COEP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COEP
    SEC Filings

    View All

    Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Z Squared Inc. (0001759186) (Filer)

    6/4/26 4:02:30 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - Z Squared Inc. (0001759186) (Filer)

    6/1/26 4:30:28 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - Z Squared Inc. (0001759186) (Filer)

    5/22/26 5:00:14 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bsg Series Cm, Llc disposed of 41,521,276 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Z Squared Inc. (0001759186) (Issuer)

    5/15/26 9:11:17 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Bsg Series Cm, Llc claimed ownership of 41,521,276 shares (SEC Form 3)

    3 - Z Squared Inc. (0001759186) (Issuer)

    5/4/26 8:05:34 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Sohn Adam Craig

    4 - Z Squared Inc. (0001759186) (Issuer)

    4/30/26 6:13:28 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market

    ~ Shares to Commence Trading on the Nasdaq Global Market Under Ticker Symbol "ZSQR" Monday April 27, 2026 ~FORT LAUDERDALE, Fla, April 24, 2026 /PRNewswire/ -- Z Squared, Inc. (NASDAQ:ZSQR) ("Z Squared" or the "Company"), a vertically integrated computing infrastructure company, today announced the completion of its business combination with Coeptis Therapeutics Holdings, Inc. ("Coeptis"). In connection with the business combination, the combined company has been renamed "Z Squared Inc." and its public shares are expected to commence trading on the Nasdaq Global Market under the ticker symbol "ZSQR" on Monday, April 27, 2026 (CUSIP: 98878K108). The closing follows the satisfaction of all con

    4/24/26 4:43:00 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application

    ~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~ WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger Company's common stock on the Nasdaq Global Market under the ticker symbol "ZSQR". The new listing is expected to become effective upon the closing of the proposed merger between the Company and Z Squared, Inc., pursuant to which Z Squared will become a wholly owned subsidiary of Coeptis and th

    4/7/26 12:05:56 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Receives Shareholder Approval Towards Z Squared Merger

    WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced that its shareholders have voted to approve the previously announced merger with Z Squared Inc. The transaction was approved on January 30, 2026, by Coeptis' shareholders. In connection with the consummation of the business combination, Z Squared will become a wholly owned subsidiary of Coeptis. The transaction remains subject to satisfaction of the remaining conditions to closing. Additional details regarding the shareholder vote and the proposed merger are included in the Company's Form 8-K f

    2/5/26 4:00:00 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Leadership Updates

    Live Leadership Updates

    View All

    Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

    Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.

    8/30/23 1:00:00 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

    15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in

    5/17/23 8:30:00 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coeptis Therapeutics Holdings Inc.

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/14/24 3:59:49 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Financials

    Live finance-specific insights

    View All

    Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

    Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat

    8/17/23 7:30:00 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care